A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 5, 2021

Study Completion Date

November 5, 2021

Conditions

Acute Intermittent Porphyria

Interventions

DRUG

Givosiran

Givosiran by subcutaneous (SC) injection.

Trial Locations (5)

Clinical Trial Site, San Francisco

Clinical Trial Site, New York

Clinical Trial Site, Galveston

Clinical Trial Site, Stockholm

Clinical Trial Site, London